Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state

Regulatory Peptides

Volumn 153, Issue 1-3, 2009, Pages 88-92

  Arnés, Luis ^a   Moreno, Paola ^a   Nuche Berenguer, Bernardo ^a   Valverde, Isabel ^a   Villanueva Peñacarrillo, Maria L ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Diabetic rat; Extrapancreatic tissues; GLP 1; Glucose transport

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 4; GLYCOGEN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCOGEN LIVER LEVEL; LIVER; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; RAT; SKELETAL MUSCLE; STREPTOZOCIN DIABETES;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLYCOGEN; LIVER; MALE; MUSCLE, SKELETAL; PEPTIDES; RATS; RATS, WISTAR; RECEPTORS, GLUCAGON; VENOMS;

ANIMALIA; RATTUS;

EID: 59849106762     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2008.08.005     Document Type: Article

References (35)

1. Eng J., Kleinman W.A., Singh L., Singh G., and Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 15 (1992) 7402-7405
2. Chen Y.E., and Drucker D.J. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 272 (1997) 4108-4115
3. Fineman M.S., Bicsak T.A., Shen L.Z., Taylor K., Gaines E., Varns A., Kim D., and Baron A.D. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26 (2003) 2370-2377
4. Nielsen L.L., Young A.A., and Parkes D.G. Pharmacology of exenatide (synthetic exedin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117 (2004) 77-88
5. Tourrel C., Bailbe D., Lacorne M., Meile M.J., Kergoat M., and Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51 (2002) 1443-1452
6. Willms B., Werner J., Holst J.J., Orskov C., Creutzfeldt W., and Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81 (1996) 327-332
7. Talsania T., Anini Y., Siu S., Drucker D.J., and Brubaker P.L. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146 (2005) 3748-3756
8. Szayna M., Doyle M.E., Betkey J.A., Holloway H.W., Spencer R.G., Greig N.H., and Egan J.M. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141 (2000) 1936-1941
9. Sancho V., Trigo M.V., González N., Valverde I., Malaisse W.J., and Villanueva-Peñacarrillo M.L. Effects of GLP-1 and exendins on kinase activity, 2-deoxy-d-glucose transport, lipolysis and lipogenesis in adipocytes from normal and streptozotocin-induced type 2 diabetic rats. J Mol Endocrinol 35 (2005) 27-38
10. Alcántara A.I., Morales M., Delgado E., López-Delgado M.I., Clemente F., Luque M.A., Malaisse W.J., Valverde I., and Villanueva-Peñacarrillo M.L. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch Biochem Biophys 341 (1997) 1-7
11. Luque M.A., González N., Márquez L., Acitores A., Redondo A., Morales M., Valverde I., and Villanueva-Peñacarrillo M.L. GLP-1 and glucose metabolism in human myocytes. J Endocrinol 173 (2002) 465-473
12. Delgado E., Luque M.A., Alcántara A., Trapote M.A., Clemente F., Galera C., Valverde I., and Villanueva-Peñacarrillo M.L. Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides 16 (1995) 225-229
13. Thorens B. Expression clonning of the pancreatic beta-cell receptor for the gluco-incretin hormone glucagon-like peptide-1. Proc Natl Acad Sci U S A 89 (1992) 8641-8645
14. Arnés L., González N., Tornero-Esteban P., Sancho V., Acitores A., Valverde I., Delgado E., and Villanueva-Peñacarrillo M.L. Characteristics of the GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle. Int J Mol Med 22 (2008) 127-132
15. Acitores A., González N., Sancho V., Valverde I., and Villanueva-Peñacarrillo M.L. Cell signalling of the glucagon like peptide-1 action in rat skeletal muscle. J Endocrinol 180 (2004) 389-398
16. González N., Acitores A., Sancho V., Valverde I., and Villanueva-Peñacarrillo M.L. Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Pept 126 (2005) 203-211
17. Villanueva-Peñacarrillo M.L., Puente J., Redondo A., Clemente F., and Valverde I. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in NIDDM and IDDM rats. Endocrine 15 (2001) 241-248
18. Portha B., Picon L., and Rosselin G. Chemical diabetes in the adult rat as the spontaneous evolution of neonatal diabetes. Diabetologia 17 (1979) 371-377
19. Vicent D., Villanueva-Peñacarrillo M.L., Valverde I., and Malaisse W.J. Impaired in vivo insulin secretion in response to non-glucidic secretagogues in adult rats after neonatal streptozotocin. Acta Diabetol 31 (1994) 133-137
20. Chun Y., and Yin Z.D. Glycogen assay for diagnosis of female genital Chlamydia trachomatis infection. J Clin Microbiol 36 (1998) 1081-1082
21. Herbert V., Lau K.S., Goltlieb C.W., and Bleicher S.J. Coated charcoal inmunoassay of insulin. J Clin Invest 25 (1956) 1375-1384
22. Valverde I., Barreto M., and Malaisse W.J. Stimulation by d-glucose of protein biosynthesis in tumoral insulin-producing cells (RINm5F line). Endocrinology 122 (1988) 1443-1448
23. Villanueva-Peñacarrillo M.L., Alcántara A., Clemente F., Delgado E., and Valverde I. Potent glycogenic effect of GLP-1 (7-36) amide in rat skeletal muscle. Diabetologia 37 (1994) 1163-1166
24. Bradford M.M. A rapid and sensitive method for the quantization of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72 (1976) 248-254
25. Dohm G.L., Tapscott E.B., Pories W.J., Dabbs D.J., Flickinger E.G., Meelheim T.F., Atkinson S.M., Elton C.W., and Caro J.F. An in vitro human muscle preparation suitable for metabolic studies. J Clin Invest 82 (1988) 486-494
26. Ascencio C., Torres N., Isoard-Acosta F., Gómez-Pérez F.J., Hernández-Pando R., and Tovar A.R. Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats. J Nutr 134 (2004) 522-529
27. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
28. Redondo A., Trigo V., Acitores A., Valverde I., and Villanueva-Peñacarrillo M.L. Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol 204 (2003) 43-50
29. Göke R., Fehmann H.C., Linn T., Schmidt H., Krause M., and Eng J. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1 (7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268 (1993) 19650-19655
30. Edwards C.M., Todd J.F., Mahmoudi M., Wang Z., Wang R.M., and Ghatei M. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48 (1999) 86-93
31. Burcelin R., Da Costa A., Drucker D., and Thorens B. Glucose competence of the heptoportal vein sensor requires the presence of an activated glucagon-like peptide 1 receptor. Diabetes 50 (2001) 1720-1728
32. Thorens B., Porret A., Bühler L., Deng S.P., Morel P., and Widmann C. Cloning and functional expression of the human islet GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin(9-39) an antagonist of the receptor. Diabetes 42 (1993) 1678-1682
33. Idris I., Patiag D., Gray S., and Donelly R. Exendin-4 increases insulin sensitivity via a PI-3-Kinase-dependent mechanism: contrasting effects of GLP-1. Biochem Pharmacol 63 (2002) 993-996
34. González N., Sancho V., Martín-Duce A., Tornero-Esteban P., Valverde I., Malaisse W.J., and Villanueva-Peñacarrillo M.L. GLP-1 signalling and effects on glucose metabolism in myocytes from type 2 diabetic patients. Int J Mol Med 16 (2005) 747-752
35. Vahl T.P., Tauchi M., Durler T.S., Elfers E.E., Fernandes T.M., Bitner R.D., Ellis K.S., Woods S.C., Seeley R.J., Herman J.P., and D'Alessio D.A. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148 (2007) 4965-4973